Thank you, Operator, and welcome to the presentation of Bactiguard's Q2 2024 report. I will go through the presentation together with our CFO, Patrick Bach, and open up for questions towards the end. Thank you all for dialing in today. I have just completed my third month as CEO of Bactiguard, and my reflection from this time is that we have a lot of the building blocks in place to execute on our new strategy. We have been through a transformation. However, the team in place is very experienced and highly motivated to make the world a healthier place. While we still have transitional activities, from the transformation to complete throughout the remainder of 2024, we are one team collaborating closely together with a solution-oriented approach and a performance mindset. Now turning to the developments of the second quarter. Let me start with the figures on an overall level. Our total revenues for Q2 amounted to $60.9 million, an increase of almost 19% compared to the same period last year. And for the first half to 119.7 million, which was an increase of 6.5% versus last year. Our license revenues are stabilizing thanks to our good partnerships with BD and Zimmer Biomet. We also report a positive EBITDA for 2024. Our EBITDA came in at 1.2 million SEK for the quarter, and net -0.3 million SEK for the six-month period. Patrick will dig deeper into the financials later in the presentation, but I want to note that we have embarked on our path towards profitability, and I am cautiously optimistic while realizing that we still have a lot to deliver. As for the highlights of the quarter, I assumed my role as CEO in April, and at the annual general meeting in May, Thomas von Koch was re-elected as chair of the board. In addition to Thomas, we are privileged to have the board that we do, supporting Bactiguard with relevant experience and knowledge, both from our industry and the medical sphere, as well as in growing profitable companies. Another important theme from the quarter is the expansion of Bactiguard coated products to new markets with BD, but also with Zimmer Biomet, including the introduction of Bactiguard in Japan. I will come back to that shortly. In July, we strengthened the organization with the appointment of Nathaniel Bachrach as interim head of R&D, and he is now a part of the Bactiguard executive management team. Tony is a product development executive with more than 25 years of experience in innovating, developing, and launching advanced medical products for global commercialization. He has been executive vice president and chief scientific officer at 3DBio Therapeutics, and previously Vice president, Research and Technology at LifeCell Corporation, where we served together on the LifeCell Leadership Team. Prior to that, he held various leadership and technical roles within LifeCell and Organogenesis Inc. Tony holds a PhD in Mechanical Engineering and Biomechanics and has an impressive record of publications and innovative patents. He is based in New Jersey in the US, and will spend his time driving our R&D strategy and in new business development. We are all excited to have Tony on board, representing Bactiguard and our technology to potential partners as part of our journey towards bringing infection prevention to patients worldwide and profitability to Bactiguard. The Bactiguard infection prevention technology, which is the essence of our company and the foundation of our licensed business, is an ultra-thin coating of the noble metals gold, silver, and palladium. The quantities of the metal are tiny. To put the quantities in perspective, the amount of noble metals equivalent to the size of a pea would coat an entire football or soccer field. When in contact with fluids, the galvanic effect created results in the inhibition of microbe adherence to the surface of medical devices. In the pictures to the right. Taken with an electron microscope. You can see the difference in bacterial colonization between an uncoated surface to the left and a Bactiguard coated surface on the right. The Bactiguard side shows significantly fewer bacteria colonizing, reducing biofilm formation over time and thus leading to lowered rates of infection. Importantly, we believe in evidence. Over the years, a wealth of data has been amassed, all pointing to the effectiveness and safety of our technology.
More than 100,000 patients have been part of over 40 clinical trials covering case reports, two randomized controlled trials, and the results have been published in renowned peer-reviewed publications. Our studies cover various patient cohorts, continents and regions, and different therapeutic areas. As we look at the global healthcare trends, our offering is more relevant today than ever. The demand for more effective and safe healthcare solutions is clear. Driven by economic and demographic developments as well as the unfortunate increase in political unrest, conflicts, wars, and natural disasters, there are clear unmet medical needs within the pressing global societal challenges we experience, including healthcare associated infections and antimicrobial resistance.
Notably, prevention strategies are, according to the World Health Organization, one of the most important factors in solving these issues. The therapeutic areas we have decided to focus on in our core strategy present huge commercial opportunities for Bactiguard. We see increasing interest in infection prevention strategies, even with our existing partnerships as examples. Urology with BD and orthopedics with Zimmer Biomet. The more we educate the market about our technology, its ability to mitigate infection risk, and how it differentiates partner medical devices, the more confident we are about the joint commercial opportunity.
Bactiguard's aim is to seize the significant opportunity presented within each of the strategic therapeutic areas, both with our infection prevention coating technology and the products within the wound management portfolio. The core of our go-forward business model is, as already mentioned, the license business. The most fundamental shift in our 2023 transformation as an organization was going from being production and sales-oriented to knowledge and specialist-focused; stabilized revenues from our partnerships with BD and Zimmer Biomet reflect more collaboration between our organizations, working together as experts, bringing and sharing knowledge with each other. There are still a lot of activities to work on, but we are on the right track when it comes to exploring new partnerships and new applications. We are active across our therapeutic areas with multiple conversations and early testing of our technology with leading medtech companies in the relevant fields.
Another crucial part is continuing to build the knowledge and specialist organization. Our core competence areas are in R&D, medical, and regulatory. These all represent critical expertise in collaboration with partners. In essence, the skills and competence needed to bring coated medical devices to the market. With the addition of Thani to our R&D organization, we enhance the combination of innovation and science with business development and have boots on the ground in the US. This is a meaningful step in strengthening our capabilities, with management remaining an important part of the business. Having delivered revenues of approximately 15 million MSEK for Q2 and continuing profitable growth. Now into the details of our partnerships on wound management during the second quarter. BD remains our longest and strongest partner. During the quarter, the transition process for additional markets for Coated Foley catheters continued according to plan, including activities such as training for BD sales and marketing teams across Europe and the Middle East. In these sessions, we shared our knowledge on how to explain the benefits of digital technology to healthcare providers and medical professionals. Doctor Gordon announced in December 2023 that we signed an interim agreement to license additional markets, and that a long-term agreement covering all licensed markets would be signed during the first half of the year. However, back to Bactiguard, BD have jointly agreed to focus primarily on the transition activities, and I want to emphasize that our existing agreements remain in full force. Turning to the Zimmer Biomet collaboration, we are pleased to see the continued market activities across Europe. But the true highlight of the quarter was the introduction of the xenon Bactiguard trauma implant at the annual meeting of the Japanese Society for Fracture Repair in Sendai, Japan. This follows the regulatory approval by the Japanese PMDA obtained in 2023, together with the Zimmer Biomet APAC commercial team. Our Chief Medical Officer and Zimmer Alliance lead were on site to introduce our infection prevention technology to leading orthopedists within the medical community in Japan, we engaged directly with nearly 40 key opinion leaders, both in one-on-one sessions and group meetings, and the Bactiguard technology was included in a presentation by Professor Watanabe to a room of hundreds of delegates. The interest in our technology was clear and underlines the growing recognition of the importance of infection prevention solutions to address critical medical needs in fracture management. While we do not expect significant contributions to revenues from the Japanese market during 2024, this is an important step in the partnership with Zimmer, and the long-term potential is promising. Within the wound management portfolio, we featured our wound healing product line, Hydrocyn aqua, in London at the European Wound Management Association conference in May. EWMA is recognized as the premier international conference for wound care, attracting leading experts, researchers, and healthcare professionals from around the world. Some 5000 attendees were registered on the opening day. We hosted a session on the latest advancements of infection prevention within wound care. The theme was Clean to Heal. Paradigm shift made easy. The interest in the product line Hydrocyn aqua is increasing. The more clinicians understand its mode of action and how it promotes healing and the quality of life for patients with severe wounds. With that, I hand over to Patrick Bach, our CFO, to review our financials in detail.